Euroopan unioni - norja - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influensavacciner - profylakse av influensa forårsaket av a (h1n1v) 2009 virus. focetria bør brukes i samsvar med offisielle veiledning.

Euroopan unioni - norja - EMA (European Medicines Agency)

seqirus s.r.l.  - influensavirusoverflateantigener, inaktivert: a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influensavacciner - profylakse av influensa i en offisielt erklært pandemisk situasjon. pandemisk influensavaksine bør brukes i henhold til offisiell veiledning.

Euroopan unioni - norja - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influensa, human - vaksiner - forebygging av influensa hos eldre (65 år og eldre). fluad tetra bør brukes i samsvar med offisielle anbefalinger.

Euroopan unioni - norja - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaksiner - active immunisation against h5 subtype of influenza a virus.

Euroopan unioni - norja - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influensavirusoverflateantigener (hemagglutinin og neuraminidase) av stamme a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaksiner - aktiv immunisering mot h5n1 subtype av influensa a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Norja - norja - Statens legemiddelverk

mylan healthcare b.v. - influensa a-virus (h1n1), inaktivert, overflateantigen / influensa a-virus (h3n2), inaktivert, overflateantigen / influensa b-virus (inaktivert, overflateantigen) - injeksjonsvæske, suspensjon - 15 mikrog/ sprøyte / 15 mikrog/ sprøyte / 15 mikrog/ sprøyte

Euroopan unioni - norja - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - influensa, human - influensa, inaktivert, split virus eller overflateantigen - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra bør brukes i samsvar med offisielle anbefalinger.

Norja - norja - Statens legemiddelverk

viatris as - influensa a-virus (h1n1), inaktivert, overflateantigen / influensa a-virus (h3n2), inaktivert, overflateantigen / influensa b-virus, victoria-linje, inaktivert,overflateantigen / influensa b-virus, yamagata-linje, inaktivert,overflateantigen - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 15 mikrog ha / 15 mikrog ha / 15 mikrog ha / 15 mikrog ha

Euroopan unioni - norja - EMA (European Medicines Agency)

merck europe b.v.  - lutropin alfa - ovulation induction; infertility, female - sex hormoner og modulatorer av genital systemet, - luveris i forbindelse med preparat for follikelstimulerende hormon (fsh) anbefales for stimulering av follikkelutvikling hos kvinner med alvorlig luteiniserende hormon (lh) og fsh-mangel. i kliniske studier, disse pasientene ble definert av en endogen serum lh nivå.

Euroopan unioni - norja - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.